ESR1 and breast cancer: These findings indicate that PRKCQ-AS1 upregulates MKP1 by serving as a molecular sponge of miR-200a-3p, and inhibiting miR-200a-3p mitigate tamoxifen resistance in ER + breast cancer cells.